Related references
Note: Only part of the references are listed.The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective
Huabo Su et al.
CARDIOVASCULAR RESEARCH (2010)
Proteasome inhibitors and cardiac cell growth
Nadia Hedhli et al.
CARDIOVASCULAR RESEARCH (2010)
Functional alterations of cardiac proteasomes under physiological and pathological conditions
Osamu Tsukamoto et al.
CARDIOVASCULAR RESEARCH (2010)
Sent to Destroy The Ubiquitin Proteasome System Regulates Cell Signaling and Protein Quality Control in Cardiovascular Development and Disease
Monte S. Willis et al.
CIRCULATION RESEARCH (2010)
Markers of Autophagy Are Downregulated in Failing Human Heart After Mechanical Unloading
Christos Kassiotis et al.
CIRCULATION (2009)
Nonsense-Mediated mRNA Decay and Ubiquitin-Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic Mice
Nicolas Vignier et al.
CIRCULATION RESEARCH (2009)
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The proteasome inhibitor Bortezomib aggravates renal ischemia-reperfusion injury
Julia M. Huber et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
The heart of autophagy - Deconstructing cardiac proteotoxicity
Beverly A. Rothermel et al.
AUTOPHAGY (2008)
The ubiquitin-proteasome system in cardiac dysfunction
Giulia Mearini et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2008)
Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy
Paul Tannous et al.
CIRCULATION (2008)
αB-Crystallin Suppresses Pressure Overload Cardiac Hypertrophy
Asangi R. K. Kumarapeli et al.
CIRCULATION RESEARCH (2008)
Regulation of the stability and transcriptional activity of NFATc4 by ubiquitination
Yongna Fan et al.
FEBS LETTERS (2008)
Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system
Silke Meiners et al.
HYPERTENSION (2008)
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
Abdullah Hacihanefioglu et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Protein quality control and degradation in cardiomyocytes
Xuejun Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2008)
Autophagy is an adaptive response in desmin-related cardiomyopathy
Paul Tannous et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Unexpected cardiotoxicity in haematological bortezomib treated patients
Enrico Orciuolo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling
Yan G. Ni et al.
CIRCULATION (2006)
Regulation of cardiac hypertrophy by intracellular signalling pathways
Joerg Heineke et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
Jens Voortman et al.
BMC CANCER (2006)
Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes
JB Liu et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake
QH Chen et al.
CIRCULATION RESEARCH (2005)
Regulation of calcineurin through transcriptional induction of the calcineurin Aβ promoter in vitro and in vivo
T Oka et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Targeted proteolysis sustains calcineurin activation
N Burkard et al.
CIRCULATION (2005)
Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy
BJ Wilkins et al.
CIRCULATION RESEARCH (2004)
In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes
X Dong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
Desmin-related cardiomyopathy in transgenic mice: A cardiac amyloidosis
A Sanbe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes
DL Hunton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Enhanced myocyte contractility and Ca2+ handling in a calcineurin transgenic model of heart failure
GX Chu et al.
CARDIOVASCULAR RESEARCH (2002)
Expression of R120G-αB-crystallin causes aberrant desmin and αB-crystallin aggregation and cardiomyopathy in mice
XJ Wang et al.
CIRCULATION RESEARCH (2001)
Mouse model of desmin-related cardiomyopathy
XJ Wang et al.
CIRCULATION (2001)
Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene.
MC Dalakas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy
T Taigen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
